- The EMA's Committee for Medicinal Products for Human Use (CHMP) adopt a positive opinion supporting approval of Imbruvica (ibrutinib) as a treatment for adult patients with relapsed or refractory mantle cell lymphoma (MCL) or adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy or as a first-line treatment in patients with the 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.
- Ibrutinib is being co-developed by Johnson & Johnson (JNJ -0.2%) unit Janssen-Cilag International NV and Pharmacyclics Switzerland GmbH. Once approved, Janssen will market it exclusively in EMEA (Europe, Middle East, Africa) and co-promote it in the U.S.
- A final decision from the European Commission usually takes ~3 months.
CHMP's positive on Imbruvica for blood cancer
From other sites
at 4-traders.com (Tue, 12:37PM)
at Nasdaq.com (Mar 16, 2015)
at Nasdaq.com (Mar 11, 2015)
at Benzinga.com (Feb 23, 2015)
at Nasdaq.com (Feb 19, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs